Role of EGFR Mutation Status in Patients with Stage III Non-squamous Non-small Cell Lung Cancer Treated with Chemoradiotherapy
Background and objective The presence of epidermal growth factor receptor (EGFR) mutations is predictive of a better response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and initial chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC). The aim of this study is to analyze the a...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2011-09-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.03 |
id |
doaj-cebc03474b154a2c9dfee070261a9b18 |
---|---|
record_format |
Article |
spelling |
doaj-cebc03474b154a2c9dfee070261a9b182020-11-24T23:52:49ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872011-09-0114971571810.3779/j.issn.1009-3419.2011.09.03Role of EGFR Mutation Status in Patients with Stage III Non-squamous Non-small Cell Lung Cancer Treated with ChemoradiotherapyFuhai LIHua BAIXia’nan LIMeina WURong YUAnhui SHILi YINJie WANGGuangying ZHUBackground and objective The presence of epidermal growth factor receptor (EGFR) mutations is predictive of a better response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and initial chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC). The aim of this study is to analyze the association between the EGFR mutations and the outcome of combined chemoradiotherapy in stage III non-squamous NSCLC. Methods Patients with stage III non-squamous NSCLC whose EGFR mutation status had been identified were retrospectively analyzed. The response of 87 patients to combined chemoradiotherapy, the two-year survival rate, and the response of 128 patients to initial chemotherapy were evaluated. Results The response rate to combined chemoradiotherapy was 84.6% (33/39) in EGFR mutation-positive patients, significantly higher than the 56.3% (27/48) response rate in EGFR mutation-negative patients (P=0.004). Two-year survival rates were 53.8% and 50% in EGFR mutation-positive and mutation-negative patients, respectively. There was no significant difference in the overall survival for both patient groups. The overall response rate to initial chemotherapy was 34.5% (19/55) in EGFR mutation-positive patients, compared with the 21.9% (16/73) response rate in EGFR mutation-negative patients. Conclusion EGFR mutation-positive status can predict better response to combined chemoradiotherapy, but is not associated with overall survival in patients with stage III non-squamous NSCLC.http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.03Lung neoplasmsChemoradiotherapyEGFRMutation |
collection |
DOAJ |
language |
zho |
format |
Article |
sources |
DOAJ |
author |
Fuhai LI Hua BAI Xia’nan LI Meina WU Rong YU Anhui SHI Li YIN Jie WANG Guangying ZHU |
spellingShingle |
Fuhai LI Hua BAI Xia’nan LI Meina WU Rong YU Anhui SHI Li YIN Jie WANG Guangying ZHU Role of EGFR Mutation Status in Patients with Stage III Non-squamous Non-small Cell Lung Cancer Treated with Chemoradiotherapy Chinese Journal of Lung Cancer Lung neoplasms Chemoradiotherapy EGFR Mutation |
author_facet |
Fuhai LI Hua BAI Xia’nan LI Meina WU Rong YU Anhui SHI Li YIN Jie WANG Guangying ZHU |
author_sort |
Fuhai LI |
title |
Role of EGFR Mutation Status in Patients with Stage III Non-squamous Non-small Cell Lung Cancer Treated with Chemoradiotherapy |
title_short |
Role of EGFR Mutation Status in Patients with Stage III Non-squamous Non-small Cell Lung Cancer Treated with Chemoradiotherapy |
title_full |
Role of EGFR Mutation Status in Patients with Stage III Non-squamous Non-small Cell Lung Cancer Treated with Chemoradiotherapy |
title_fullStr |
Role of EGFR Mutation Status in Patients with Stage III Non-squamous Non-small Cell Lung Cancer Treated with Chemoradiotherapy |
title_full_unstemmed |
Role of EGFR Mutation Status in Patients with Stage III Non-squamous Non-small Cell Lung Cancer Treated with Chemoradiotherapy |
title_sort |
role of egfr mutation status in patients with stage iii non-squamous non-small cell lung cancer treated with chemoradiotherapy |
publisher |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
series |
Chinese Journal of Lung Cancer |
issn |
1009-3419 1999-6187 |
publishDate |
2011-09-01 |
description |
Background and objective The presence of epidermal growth factor receptor (EGFR) mutations is predictive of a better response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and initial chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC). The aim of this study is to analyze the association between the EGFR mutations and the outcome of combined chemoradiotherapy in stage III non-squamous NSCLC. Methods Patients with stage III non-squamous NSCLC whose EGFR mutation status had been identified were retrospectively analyzed. The response of 87 patients to combined chemoradiotherapy, the two-year survival rate, and the response of 128 patients to initial chemotherapy were evaluated. Results The response rate to combined chemoradiotherapy was 84.6% (33/39) in EGFR mutation-positive patients, significantly higher than the 56.3% (27/48) response rate in EGFR mutation-negative patients (P=0.004). Two-year survival rates were 53.8% and 50% in EGFR mutation-positive and mutation-negative patients, respectively. There was no significant difference in the overall survival for both patient groups. The overall response rate to initial chemotherapy was 34.5% (19/55) in EGFR mutation-positive patients, compared with the 21.9% (16/73) response rate in EGFR mutation-negative patients. Conclusion EGFR mutation-positive status can predict better response to combined chemoradiotherapy, but is not associated with overall survival in patients with stage III non-squamous NSCLC. |
topic |
Lung neoplasms Chemoradiotherapy EGFR Mutation |
url |
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.03 |
work_keys_str_mv |
AT fuhaili roleofegfrmutationstatusinpatientswithstageiiinonsquamousnonsmallcelllungcancertreatedwithchemoradiotherapy AT huabai roleofegfrmutationstatusinpatientswithstageiiinonsquamousnonsmallcelllungcancertreatedwithchemoradiotherapy AT xiananli roleofegfrmutationstatusinpatientswithstageiiinonsquamousnonsmallcelllungcancertreatedwithchemoradiotherapy AT meinawu roleofegfrmutationstatusinpatientswithstageiiinonsquamousnonsmallcelllungcancertreatedwithchemoradiotherapy AT rongyu roleofegfrmutationstatusinpatientswithstageiiinonsquamousnonsmallcelllungcancertreatedwithchemoradiotherapy AT anhuishi roleofegfrmutationstatusinpatientswithstageiiinonsquamousnonsmallcelllungcancertreatedwithchemoradiotherapy AT liyin roleofegfrmutationstatusinpatientswithstageiiinonsquamousnonsmallcelllungcancertreatedwithchemoradiotherapy AT jiewang roleofegfrmutationstatusinpatientswithstageiiinonsquamousnonsmallcelllungcancertreatedwithchemoradiotherapy AT guangyingzhu roleofegfrmutationstatusinpatientswithstageiiinonsquamousnonsmallcelllungcancertreatedwithchemoradiotherapy |
_version_ |
1725471786613604352 |